Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029

M. Surdo, C. Alteri, M. C. Puertas, P. Saccomandi, L. Parrotta, L. Swenson, D. Chapman, G. Costa, A. Artese, E. Balestra, S. Aquaro, S. Alcaro, M. Lewis, B. Clotet, R. Harrigan, H. Valdez, V. Svicher, C. F. Perno, J. Martinez-Picado, F. Ceccherini-Silberstein

Research output: Contribution to journalArticle

Abstract

We characterized maraviroc susceptibility of dual/mixed tropic viruses from subjects enrolled onto phase IIb study A4001029. Maraviroc baseline plasma samples from 13 multidrug-experienced subjects were sequenced and the HIV-1-env gene cloned into pNL4.3Δenv to obtain recombinant viruses. The V3 region was sequenced by the Sanger method and ultradeep sequencing. By analysing subjects having a weighted optimized background therapy susceptibility (wOBT) score of

Original languageEnglish
JournalClinical Microbiology and Infection
Volume21
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Keywords

  • Dual/mixed virus
  • HIV
  • maraviroc
  • phenotypic activity
  • UDPS

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029'. Together they form a unique fingerprint.

  • Cite this

    Surdo, M., Alteri, C., Puertas, M. C., Saccomandi, P., Parrotta, L., Swenson, L., Chapman, D., Costa, G., Artese, A., Balestra, E., Aquaro, S., Alcaro, S., Lewis, M., Clotet, B., Harrigan, R., Valdez, H., Svicher, V., Perno, C. F., Martinez-Picado, J., & Ceccherini-Silberstein, F. (2015). Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029. Clinical Microbiology and Infection, 21(1). https://doi.org/10.1016/j.cmi.2014.08.002